Syngene International Ltd. · NSE:SYNGENE

Syngene International — Investor Presentation (August 2015)

30 slides from Syngene International's investor presentation, August 2015

  1. Slide 1: Investor Presentation

    Investor Presentation August 2015 Strictly confidential & privileged

  2. Slide 2: Safe Harbour

    Safe Harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements

  3. Slide 3: Highlights

    Highlights 1 Introduction 2 Industry Overview 3 Investment Thesis 4 Financial Highlights 3

  4. Slide 4: Introduction

    Introduction . 7 . + " » * * . waa eas! Putting Science to Work

  5. Slide 5: The Biocon Group

    The Biocon Group THE BIOCON GROUP Listed since 2004, Market Cap ~INR 92.3bn(1)  Biosimilars  Contract Discovery Product Service  Formulations and Compounds  Contract Development Based Based  Alternative Therapeutic Drugs  Contract Manufacturing 5 (1) As of 30th June 2015 Strictly confidential

  6. Slide 6: Ownership Structure

    Ownership Structure  Total number of shares: 200 Mn  Promoter : Biocon Group(1) Biocon ESOP 1.0%  Public consists of - Syngene ESOP 3.3% Promoter o Silver leaf : 10% 73.5% Public o Other Shareholders : 12.2% 22.2% 6 (1) Includes stake of Biocon Limited, Biocon Research Limited and Kiran Mazumdar

  7. Slide 7: Syngene – 21 Years of Growth and Expansion

    Syngene – 21 Years of Growth and Expansion 20,000 sq ft facility Over 900,000 sq ft facility Infrastructure 100+ 2,700+ People - Chemistry - Early biology - End-to-End discovery, development and - Simple biology laboratory manufacturing capabilities Capabilities $5 million $150 million Investment 7

  8. Slide 8: Who We Are Today: A Global High Growth CRO Company

    Who We Are Today: A Global High Growth CRO Company One of the leading India-based CROs Strong Growth and Profitability Integrated discovery and development platform Focus on novel molecular entities 8,716 221(1) clients across multiple sectors 7,077 5,542 95%(1) of revenues from outside India 4,182

  9. Slide 9: Recent Business Highlights

    Recent Business Highlights All figures in INR Mn unless otherwise specified  Entered into 3 long-term contracts with two existing P&L Summary Q1 FY16 Q1 FY15 YoY Change clients for commercial manufacturing of their novel Revenue 2,358 1,833 29% small molecules EBITDA 770 618 25%  Extended our long

  10. Slide 10: Industry Overview

    Industry Overview . . 7 . + " » * * . waa eas! Putting Science to Work

  11. Slide 11: Global Pharma R&D Trends

    Global Pharma R&D Trends  Large and growing addressable market Industry Statistics  Global R&D expenditure expected to increase from (US$bn) $139bn in 2014 to $152bn in 2018 (CAGR of 2.3%) Global R&D Spending Global CRO Market(1)  75% of R&D spend can be potentially outsourced 45  Increasing per

  12. Slide 12: Investment Thesis

    Investment Thesis . . 7 . + " » * * . waa eas! Putting Science to Work

  13. Slide 13: What Makes Syngene A Unique Investment case?

    What Makes Syngene A Unique Investment case? INTEGRATED MODEL Integrated and flexible model provides predictability and scalability WORLD CLASS INFRASTRUCTURE & SCIENTISTS World class infrastructure, high standards of quality systems and a highly talented pool of scientists underpins the continuous

  14. Slide 14: Fully Integrated Services Platform

    Fully Integrated Services Platform Discovery Development Manufacturing Drug Substance Chemistry Development Clinical Supplies Small Molecules Drug Product Development Biology Integrated Drug Substance – Specialty Molecules Drug Product Integrated drug discovery Clinical Services (India) Commercial S

  15. Slide 15: Integrated platform with multiple entry points

    Integrated platform with multiple entry points Entry points create opportunity for customer engagement expansion Discovery Development Commercialisation Pre- clinical Clinical Target Lead Product Identification Generation Animal Ph Ph Ph Drug filing launch Lead Safety I II III with FDA & other globa

  16. Slide 16: Integrated platform enables us to build strategic relationships

    Integrated platform enables us to build strategic relationships 16

  17. Slide 17: CRO industry has high barriers to entry

    CRO industry has high barriers to entry R&D and Manufacturing Infrastructure Conform with international accreditations Focus on Quality Quality certified processes and instruments Intellectual Property Protection Strong IP and confidentiality procedures Scientist Talent Ability to attract global sci

  18. Slide 18: World-class R&D & Manufacturing Facilities

    World-class R&D & Manufacturing Facilities Infrastructure Qualified to Meet International Standards Key accreditations USFDA EMA  Over 900,000 sq. ft. of labs and manufacturing facilities audited audited  INR 9,569 Mn(1) total tangible fixed assets (gross block) ISO ISO  End-to-end discovery and

  19. Slide 19: Talented and Qualified Pool of Scientists

    Talented and Qualified Pool of Scientists Highly Experienced and Qualified Team of Scientists has 12% of scientist pool with a Doctorate & 82% with a Master’s Degree Helped Syngene Create a Competitive Edge over its Peers Others Ph.Ds.  Ability to attract and retain high-quality scientists 120 253

  20. Slide 20: Attractive Blue Chip Customer Base

    Attractive Blue Chip Customer Base  Highly successful track-record in molecule Services to 221 Clients (FY15) development Across Various Sectors  Client base includes 8 of the top 10 global pharma company by 2014 sales(1) Pharmaceutical  8 of our top 10 clients have been associated for Biotechnol

  21. Slide 21: Long Term Relationships: Dedicated Research Centres

    Long Term Relationships: Dedicated Research Centres Largest R&D Centre in Asia for BMS Dedicated research centre in India for Abbott Nutrition’s 1st R&D centre in India (2009). Contract extended till 2020. Baxter (2013). set up in collaboration with Syngene (2012). Dedicated centre of research excel

  22. Slide 22: Multiple Layers of Growth

    Multiple Layers of Growth Expand/Extend existing clients Capacity Expansion - High service integration - Consistent expansion - Dedicated centres model - FTE services, manufacturing, formulation, biologics, stability Engage New Clients - Tailored service offerings and Customer Capacity dedicated per

  23. Slide 23: Financial Highlights

    Financial Highlights . . 7 . + " » * * . waa eas! Putting Science to Work

  24. Slide 24: Strong Track Record Of Topline Growth…

    Strong Track Record Of Topline Growth…  Growth driven by increase in sales from Total Revenue (INRm) existing clients and acquisition of new clients  “Engage, expand and extend” strategy to extend client relationship over a longer 8,716 period of time 7,077  Growth in total number of clients 5,54

  25. Slide 25: …With Best-in-Class Profitability

    …With Best-in-Class Profitability Operating Margin (EBITDA) Profit After Tax Margin (Net Income) 20% 34% 34% 19% 17% 18% 31% 31% 30% 2,928 1,750 2,217 9% 1,339 1,682 976 1,404 727 1,005 283 FY2011 FY2012 FY2013 FY2014 FY2015 FY2011 FY2012 FY2013 FY2014 FY2015 EBITDA (INRm) EBITDA Margin Net Income (

  26. Slide 26: Capital Expenditure

    Capital Expenditure Historical Capital Investments – Average Gross Block (INRm) Planned Capital Expenditure 8,255  Capex of US$200 million envisaged over FY16 to FY18 5,610 6,149 6,819 5,216  Future funding requirements to be met through internal accruals and debt FY2011 FY2012 FY2013 FY2014 FY201

  27. Slide 27: Efficient Use of Capital

    Efficient Use of Capital  Strong Balance Sheet with a Return on Capital Employed (ROCE)* Balance Sheet Balance Sheet Highlights Highlights Net cash of 977 Mn 22.6% 21.6% As on 30th June 2015 (INR Mn) 20.1% 20.2%  Profitability resulting in high return on capital Shareholders’ funds 8,900 12.9%  F

  28. Slide 28: Summary: What Makes Syngene a Unique Investment Case?

    Summary: What Makes Syngene a Unique Investment Case? INTEGRATED MODEL Integrated and flexible model provides predictability and scalability WORLD CLASS INFRASTRUCTURE & SCIENTISTS World class infrastructure, high standards of quality systems and a highly talented pool of scientists underpins the co

  29. Slide 29: Managing Risks

    Managing Risks Risk Mitigation Client growth and sustained retention Proactive client engagement and sustained quality Currency Fluctuation (USD/INR) comprehensive hedging policy and mechanism in place Significant Capex investment over next few years staggered investments in line with business visib

  30. Slide 30: THANK YOU

    THANK YOU For more details www.syngeneintl.com • Visit www.syngeneintl.com • IR Contact : Sweta Pachlangiya +91 80 2808 5481 [email protected]

Syngene International — Investor Presentation (August 2015) on 6ix